Abstract:The Epstein-Barr virus (EBV) is thought to be one of tumorigenic viruses, which can be detected in many kinds of lymphomas, such as extranodal NK/T-cell lymphoma and Burkitt lymphoma. Those EBV positive lymphomas are also called EBV-associated lymphomas. Some studies showed that patients with EBV-associated lymphoma had a worse prognosis. Dysfunction of T cells may contribute to failure of immune surveillance and tumorigenesis. Therefore, this study was aimed to investigate T cell dysfunction in patients with EBV-associated lymphoma. Peripheral blood was collected from 20 patients with EBV-associated lymphoma and 10 healthy donors (healthy EBV seropositive donors) at the Peking University First Hospital. First, the phenotypes and ratios of PBMCs were analyzed using flow cytometry. Compared with healthy donors, the proportion of CD3+ T cells were little lower in the patients, but had no significantly difference (healthy donors vs patients, 47.82±6.85% vs 34.43±3.63%, p=0.09). The ratios of CD4+ T cells / CD8+ T cells were significantly decreased in the patients, the proportion of CD4+ T cells in CD3+ T cells were decreased (healthy donors vs patients, 59.40±3.84% vs 29.46±2.84%, p<0.0001), and CD8+T cells in CD3+T cells were increased (healthy donors vs patients, 33.94±3.60% vs 57.36±2.59%, p=0.0003) in the patients. NK cells had no significantly difference between the two groups (healthy donors vs patients, 9.74±3.68% vs 10.37±2.16%, p=0.88). Further, an enzyme-linked immunospot assay revealed that the production of IFN-γ in T cells was remarkably reduced upon stimulation with EBV mixed peptides, suggesting EBV specific T responses were insufficient in the patients with EBV-associated lymphoma. To study the mechanism of T cells dysfunction in EBV-associated lymphoma, multiple inhibitory receptors were analyzed. Compared with healthy donors, we found that CD4+ T cells and CD8+ T cells expressed higher levels of PD-1, LAG-3, TIM-3 and CTLA-4 in the patients, suggesting T cells were exhausted in the patients with EBV-associated lymphoma. Furthermore, the T-bethi PD1mid exhausted T cells which can be rescued by blockade of PD1 pathway and the EOMEShi PD1hi exhausted T cells which can not be rescued by the blockade of PD1 pathway were both higher in the patients with EBV-associated lymphoma. CD57+KLRG-1+CD160+CD28- were markers of T cell senescence, we found this subset cells were also a little higher in patients, suggesting that T cell senescence might be another contributor of T cell dysfunction in the patients with EBV-associated lymphoma. In addition, some studies have demonstrated that exhausted T cells do not derive from the ‘senescent’ KLRG-1+ subset of effector T cells but rather from the CD127+ subset of memory precursors that are present in the effector phase. We found the proportion of CD127+ T cells reduced significantly in the patients, further suggesting memory T cells decreased and exhausted T cells increased in the patients with EBV-associated lymphoma. All together, we demonstrated here that T cell dysfunction was the predominant feature of the patients with EBV-associated lymphoma, including the T cells ratio imbalance and T cell exhaustion. Our study contributes to understand the pathogenesis of EBV-associated lymphoma and suggests that immune checkpoint blockade may be warranted.

Lymphocytes in Patients with Chronic Active Epstein-Barr Virus Disease Exhibited Elevated PD-1/PD-L1 Expression and a Prevailing Th2 Immune Response

LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE.

Epstein-Barr Virus Variation in People Living with Human Immunodeficiency Virus in Southeastern China.

Clinical analysis of Epstein-Barr virus-associated lymphoproliferative disease in children

Clinical Characteristics of Peripheral Lymphocyte Subtypes in Chronic Active Epstein-Barr Virus Infection

[Clinical and Laboratory Characteristics of Chronic Active Epstein-Barr Virus Infection in Children].

T Cell Dysfunction in Epstein-Barr Virus-Associated Lymphoma

Case report: Immune modulation after PD-1 inhibitor therapy in a patient with extranodal NK/T-cell lymphoma secondary to chronic active Epstein-Barr virus disease unveiled by single-cell transcriptomics

Increased expression of the TLR7/9 signaling pathways in chronic active EBV infection

Restricted diversification of T-cells in chronic active Epstein-Barr virus infection: potential inclination to T-lymphoproliferative disease

Patients with Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have a Unique Phenotype, With Increased Activation of the PI3K/Akt/mTOR and STAT1 Pathways and Immature NK Cells

Clinical Features and Prognosis of Acute Lymphoblastic Leukemia in Children with Epstein-Barr Virus Infection.

Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Features Disrupted Antigen Capture/presentation and Hijacked T-cell Suppression

Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis

Expression of the immune checkpoint molecules PD‑L1 and PD‑1 in EBV‑associated lymphoproliferative disorders: A meta‑analysis

T Cell Exhaustion and Senescence in Epstein-Barr Virus-Associated Lymphoma Patients

Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact

Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

Clinical characteristics of 111 patients with chronic active Epstein-Barr virus infection

Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease